Telmisartan enhances mitochondrial activity and alters cellular functions in human coronary artery endothelial cells via AMP-activated protein kinase pathway

Atherosclerosis

Volumn 239, Issue 2, 2015, Pages 375-385

  Kurokawa, Hirofumi ^a   Sugiyama, Seigo ^a   Nozaki, Toshimitsu ^a   Sugamura, Koichi ^a   Toyama, Kensuke ^a   Matsubara, Junichi ^a   Fujisue, Koichiro ^a   Ohba, Keisuke ^a   Maeda, Hirofumi ^a   Konishi, Masaaki ^a   Akiyama, Eiichi ^a   Sumida, Hitoshi ^a   Izumiya, Yasuhiro ^a   Yasuda, Osamu ^b   Kim Mitsuyama, Shokei ^a   Ogawa, Hisao ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

AMPK; Endothelial function; ENOS; Mitochondria; Senescence

Indexed keywords

CATALASE; CYTOCHROME C; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; NUCLEAR RESPIRATORY FACTOR 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN BCL 2; TELMISARTAN; VASCULOTROPIN A; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; BETA GALACTOSIDASE; NITRIC OXIDE SYNTHASE;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CELL FUNCTION; CELL VIABILITY; CONTROLLED STUDY; CORONARY ARTERY; ENDOTHELIUM CELL; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; CELL AGING; CELL CULTURE; CHEMISTRY; CORONARY BLOOD VESSEL; CYTOLOGY; DRUG EFFECTS; GENE DELETION; METABOLISM; RNA INTERFERENCE;

AMP-ACTIVATED PROTEIN KINASES; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BETA-GALACTOSIDASE; CELL AGING; CELLS, CULTURED; CORONARY VESSELS; ENDOTHELIAL CELLS; GENE DELETION; HUMANS; MITOCHONDRIA; NITRIC OXIDE SYNTHASE; RNA INTERFERENCE;

EID: 84922572285     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.01.037     Document Type: Article

References (31)

1. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
2. Akiyama E., Sugiyama S., Matsuzawa Y., et al. Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction. J.Am. Coll. Cardiol. 2012, 60:1778-1786.
3. Chan S.Y., Mancini G.B.J., Kuramoto L., et al. The prognostic importance of endothelial dysfunction and carotid atheromaburden in patients with coronary artery disease. J.Am. Coll. Cardiol. 2003, 42:1037-1043.
4. Matsuzawa Y., Sugiyama S., Sumida H., et al. Peripheral endothelial function and cardiovascular events in high-risk patients. J.Am. Heart Assoc. 2013, 2. e000426.
5. Nozaki T., Sugiyama S., Koga H., et al. Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease. J.Am. Coll. Cardiol. 2009, 54:601-608.
6. Schachinger V., Britten M.B., Zeiher A.M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000, 101:1899-1906.
7. Vita J.A. Endothelial function and clinical outcome. Heart 2005, 91:1278-1279.
8. Bakris G., Burgess E., Weir M., et al. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int. 2008, 74:364-369.
9. Lin J.W., Chang C.H., Caffrey J.L., et al. Examining the Association of Olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality. Hypertension 2014, 63:968-976.
10. Souza-Mello V., Gregorio B.M., Cardoso-de-Lemos F.S., et al. Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet. Clin. Sci. (Lond) 2010, 119:239-250.
11. Sugimoto K., Qi N.R., Kazdova L., et al. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 2006, 47:1003-1009.
12. Davidson S.M., Duchen M.R. Endothelial mitochondria: contributing to vascular function and disease. Circ. Res. 2007, 100:1128-1141.
13. Madamanchi N.R., Runge M.S. Mitochondrial dysfunction in atherosclerosis. Circ. Res. 2007, 100:460-473.
14. Chan S.H.H., Wu K.L.H., Chang A.Y.W., et al. Oxidative impairment of mitochondrial electron transport chain complexes in rostral ventrolateral medulla contributes to neurogenic hypertension. Hypertension 2008, 53:217-227.
15. Kelley D.E., He J., Menshikova E.V., et al. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 2002, 51:2944-2950.
16. Petersen K.F., Dufour S., Befroy D., et al. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N.Engl. J. Med. 2004, 350:664-671.
17. Fisslthaler B., Fleming I. Activation and signaling by the AMP-activated protein kinase in endothelial cells. Circ. Res. 2009, 105:114-127.
18. Kahn B.B., Alquier T., Carling D., et al. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005, 1:15-25.
19. Schulz E., Dopheide J., Schuhmacher S., et al. Suppression of the JNK pathway by induction of a metabolic stress response prevents vascular injury and dysfunction. Circulation 2008, 118:1347-1357.
20. Feng X., Luo Z., Ma L., et al. Angiotensin II receptor blocker telmisartan enhances running endurance of skeletal muscle through activation of the PPAR-delta/AMPK pathway. J.Cell. Mol. Med. 2011, 15:1572-1581.
21. Wang P., Henning S.M., Heber D. Limitations of MTT and MTS-based assays for measurement of antiproliferative activity of green tea polyphenols. PLoS One 2010, 5:e10202.
22. Benson S.C., Pershadsingh H.A., Ho C.I., et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004, 43:993-1002.
23. Scalera F., Martens-Lobenhoffer J., Bukowska A., et al. Effect of telmisartan on nitric oxide-asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging. Hypertension 2008, 51:696-703.
24. Kurtz T.W. Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta Diabetol. 2005, 42(Suppl.1):S9-S16.
25. Toba H., Wang J., Ohigashi M., et al. Telmisartan protects against vascular dysfunction with peroxisome proliferator-activated receptor-gamma activation in hypertensive 5/6 nephrectomized rats. Pharmacology 2013, 92:265-275.
26. Myojo M., Nagata D., Fujita D., et al. Telmisartan activates endothelial nitric oxide synthase via Ser1177 phosphorylation in vascular endothelial cells. PLoS One 2014, 9:e96948.
27. Takeuchi K., Yamamoto K., Ohishi M., et al. Telmisartan modulates mitochondrial function in vascular smooth muscle cells. Hypertens. Res. 2013, 36:433-439.
28. Siragusa M., Sessa W.C. Telmisartan exerts pleiotropic effects in endothelial cells and promotes endothelial cell quiescence and survival. Arterioscler. Thromb. Vasc. Biol. 2013, 33:1852-1860.
29. Kitta Y., Obata J.E., Nakamura T., et al. Persistent impairment of endothelial vasomotor function has a negative impact on outcome in patients with coronary artery disease. J.Am. Coll. Cardiol. 2009, 53:323-330.
30. Zhou G., Myers R., Li Y., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J.Clin. Investig. 2001, 108:1167-1174.
31. Jin J., Mullen T.D., Hou Q., et al. AMPK inhibitor compound C stimulates ceramide production and promotes Bax redistribution and apoptosis in MCF7 breast carcinoma cells. J.Lipid Res. 2009, 50:2389-2397.